Summary & Overview

HCPCS J7171: Recombinant ADAMTS13 Injection, 10 IU

HCPCS Level II code J7171 denotes a 10 IU injectable dose of recombinant ADAMTS13 (adamts13, recombinant-krhn), a targeted biologic therapy used in conditions characterized by severe ADAMTS13 deficiency. The code is important nationally as it standardizes billing for a specialized therapeutic agent administered in outpatient infusion settings or hospital outpatient departments. Accurate use of J7171 affects coverage determinations, specialty pharmacy coordination, and claims processing for high-cost biologic therapy.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and service setting, common modifier considerations, and what typical documentation and service lines relate to this drug administration. The publication also outlines payer policy areas often relevant to high-cost injectable biologics—prior authorization pathways, medical versus pharmacy benefit determinations, and site-of-service implications—while noting where input data is not available.

This summary equips coding, billing, and revenue integrity teams with the essential framing for J7171, clarifying its clinical indication, common sites of administration, and the payer landscape to inform claim setup, reimbursement expectations, and operational workflows.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7171HCPCS Level IIrecombinant ADAMTS13infusionbiologic therapyoutpatient administrationdrug billinghigh-cost drugtherapeutic injection

Billing Code Overview

HCPCS Level II code J7171 represents an injection of recombinant ADAMTS13 (adamts13, recombinant-krhn) in a unit dose of 10 international units (IU). This code describes the administration of a recombinant enzyme replacement intended to address severe ADAMTS13 deficiency or related thrombotic microangiopathy conditions.

Service Type: Therapeutic biologic injection

Typical Site of Service: Hospital outpatient department or infusion center

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult admitted to an inpatient hematology or tertiary care medical center with acquired thrombotic thrombocytopenic purpura (aTTP) confirmed by severe ADAMTS13 deficiency and presence of ADAMTS13 autoantibodies. The patient presents with microangiopathic hemolytic anemia, thrombocytopenia, and organ ischemia (eg, neurologic symptoms, renal dysfunction). Initial management includes plasma exchange and immunosuppression (corticosteroids, rituximab). Recombinant ADAMTS13 (J7171) is administered as an intravenous injection in measured international units to restore ADAMTS13 activity when available under approved indications or investigational protocols.

Care pathway and workflow:

Admission to inpatient unit or specialty infusion center for acute aTTP or for scheduled replacement/maintenance dosing.
Baseline documentation: diagnosis codes, baseline labs (CBC, LDH, creatinine, haptoglobin), ADAMTS13 activity and inhibitor testing, consent for therapy if required.
Pharmacy preparation and verification of J7171 dose (10 IU vials or multiples) and shelf‑handling per manufacturer guidance.
Administration by trained infusion nurse under hematology oversight. Typical site of service is inpatient hospital, observation unit, or hospital-based infusion center. Dosing frequency and duration are determined by treating hematologist and protocol.
Monitoring during and after injection for infusion reactions, hemolysis parameters, platelet recovery, and organ function. Documentation includes lot number, units administered, route (intravenous), and any applicable modifier (eg, wasted product reported with JW).

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered to patient	Use when portions of reconstituted `J7171` are discarded and payer allows reporting of discarded biologic units.

JZ | No drug product wastage; entire amount administered | Use when the exact amount prepared was fully administered with no discard.

QK | Intravenous push via non-implantable catheter | Use when J7171 is administered as an IV push and payer requires this modifier for reporting infusion technique.

QX | Advanced practice provider (PA/NP) service: performed under their own NPI | Use when a PA or NP administers or supervises the infusion under billing rules requiring QX.

QY | Locum tenens physician service | Use when a locum tenens physician provides oversight for the infusion service.

JW and JZ are both included above to distinguish wasted vs fully administered product.

62 | Two surgeons | Use rarely — only if two distinct physicians of different specialties both report operative-level participation during a related procedure (not typical for infusion-only but applicable if procedure combined with surgical intervention).

78 | Unplanned return to OR following initial procedure | Use only when an unplanned return to the operating room occurs for a procedure related to complications of therapy.

80 | Assistant surgeon | Use when an assistant surgeon is required during a related operative procedure.

AS | Physician assistant, nurse practitioner, or clinical nurse specialist services in lieu of physician | Use when billing rules require identification of these providers for the infusion encounter.

FY | Leftover—manufacturer or provider specific reporting (use per payer rules) | Use per payer guidance where specific reporting for patient-specific biologic programs is required.

Taxonomy Code	Specialty	Notes
`207RH0000X`	Hematology	Hematologists direct diagnosis and therapy for aTTP and recombinant ADAMTS13 use.

2080P0207X | Medical Oncology | Oncology/hematology infusion services and complex co-management in cancer centers.

163W00000X | Pediatric Hematology-Oncology | Pediatric specialists managing congenital or acquired ADAMTS13 deficiency in children.

363L00000X | Hospitalist | Inpatient physicians coordinating care, orders, and monitoring during inpatient administration.

3336P0800X | Clinical Nurse Specialist | Advanced nursing staff involved in infusion administration and monitoring.

OpenPayer